Nov 07 (Reuters) - Adaptive Biotechnologies Q3 revenue USD 46.435 million vs. IBES estimate USD 40.2 million.
- Q3 operating income USD -32.632 million vs. IBES estimate USD -43.2 million
- Q3 net income USD -32.097 million vs. IBES estimate USD -43.9 million
- Q3 operating expenses USD 79.067 million
- Q3 adjusted EBITDA USD -14.3 million vs. IBES estimate USD -23.6 million